MetaCap

Bambusa Therapeutics (BBTX) vs Immatics N.V. (IMTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immatics N.V. is the larger company by market cap ($878.6 million vs $815.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBTX+6.74%IMTX-19.86%
+16%-3%-22%
Oct 30, 20261 yearNov 20, 2026
BBTX+6.74%IMTX-19.86%
+9%-6%-21%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBTX versus IMTX key metrics
MetricBBTXIMTX
Share price$16.00$5.77
Market cap$815.08M$878.58M
1-day change+2.89%-3.03%
YTD return—-45.05%
1-year return—-43.43%
5-year return—-48.57%
EPS (TTM)$-1.73$-1.95
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$17.65$12.41
52-week low$13.60$5.72
Distance from 52-week high-9.35%-53.51%
Analyst consensus—strong_buy
Avg. price target upside—+176.78%
Average volume359.41K962.74K
Shares outstanding50.94M152.27M
Employees26721
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Bambusa Therapeutics

BBTX stock →

Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 26 employees

About Immatics N.V.

IMTX stock →

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 721 employees

BBTX vs IMTX FAQ

Which is bigger, Bambusa Therapeutics or Immatics N.V.?

Immatics N.V. (IMTX) is larger, with a market capitalization of $878.58M compared with $815.08M for Bambusa Therapeutics (BBTX).

Are Bambusa Therapeutics and Immatics N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons